Plain-English translation of NCT07472972 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lymphoma research guide →CAR T cell therapy is a newer treatment for certain blood cancers where your own immune cells are redesigned to fight lymphoma. However, many patients don't respond well to the treatment or their cancer comes back within weeks. This study is testing a new tool called the INTeRCePT assay—a blood test that can identify early warning signs of whether the treatment is working, so doctors can make better decisions about your care right after you receive it.
Most patients who don't respond to this medication fail treatment within the first 90 days after receiving it. By catching these high-risk patients earlier through a special blood test, doctors hope to offer additional treatments or adjustments at a time when they're most likely to help.
You likely qualify if…
You likely don't qualify if…
You would receive CAR T cell therapy according to your doctor's standard treatment plan. During your regular follow-up visits over the next several weeks, you would donate blood samples and possibly tissue samples so researchers can run the new INTeRCePT assay test. The study focuses on collecting these samples within a specific timeframe (by day 38 after treatment) to see if the new test can be completed reliably. Your doctor will not change your treatment based on these test results in this study, but the information gathered will help design future trials where the test results might guide treatment decisions.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
Switzerland